A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects With Unresectable or Metastatic Advanced Solid Tumors
Latest Information Update: 27 Dec 2023
At a glance
- Drugs CAN 1012 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors CanWell Pharma
- 18 Dec 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2024.
- 18 Dec 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2024.
- 28 Jan 2022 Status changed from not yet recruiting to recruiting.